Comparative study on the immunogenicity between an HLA-A24-restricted cytotoxic T-cell epitope derived from survivin and that from its splice variant survivin-2B in oral cancer patients.
about
Expression of survivin detected by immunohistochemistry in the cytoplasm and in the nucleus is associated with prognosis of leiomyosarcoma and synovial sarcoma patients.The proto-oncogene survivin splice variant 2B is induced by PDGF and leads to cell proliferation in rheumatoid arthritis fibroblast-like synoviocytes.Cisplatin tumor biodistribution and efficacy after intratumoral injection of a biodegradable extended release implant.Genetic mutations of GJB2 and mitochondrial 12S rRNA in nonsyndromic hearing loss in Jiangsu Province of China.The functioning antigens: beyond just as the immunological targets.Developing regional genetic counseling for southern Chinese with nonsyndromic hearing impairment: a unique mutational spectrum.Antimicrobial peptides and skin: a paradigm of translational medicine.The current landscape of adipose-derived stem cells in clinical applications.Genetic hearing impairment.CD20 alternative splicing isoform generates immunogenic CD4 helper T epitopes.Chitosan-EDTA new combination is a promising candidate for treatment of bacterial and fungal infections.Prevalence of GJB2 mutations in the Silk Road region of China and a report of three novel variants.Beneficial effects of an Andrographis paniculata extract and andrographolide on cognitive functions in streptozotocin-induced diabetic rats.Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer.Survivin-Based Treatment Strategies for Squamous Cell Carcinoma.Evaluation of thermal-oxidative stability and antiglioma activity of Zanthoxylum tingoassuiba essential oil entrapped into multi- and unilamellar liposomes.
P2860
Q54807880-691DFAA2-BBBB-42AE-8F75-33CBACFB8367Q54807881-B51B468C-0CBD-40A1-A02C-4D44289B4D1BQ54936575-E8CEEC84-56DC-4AF9-A8F2-665AF5FD279DQ54936583-687970E0-C71D-4A5B-AED6-6A0DACBBCF99Q54936585-6A2ACEA3-8E26-4A63-9613-D9DEE396386AQ54936587-751F9D6C-BB66-40C0-A8D2-40038ED212BAQ54936591-DF89A7B9-B1D3-49F2-8608-A5C8C32BEBEF
P1343
Q33533999-0AA1DC66-DB1D-4E9E-941E-3B5A5307D85BQ35635793-0E7CD276-B2D0-4C57-B2BB-0C1FCD4DFBA2Q35692165-FFF74C81-372B-4E2B-9D5C-79282FAFBFD4Q36996644-A681B28F-6B35-419F-B9E7-A6FB252B1A6DQ37483795-9C7D8AC9-6188-47F6-BF4C-8E568B716275Q37683761-48D89135-22AC-4595-AE9E-DECF51F97EAAQ38042296-638DB64A-D899-4AE9-A138-69E9F58B696EQ38210142-3FE2E151-E582-41CA-A556-72D620CFD75EQ38357444-C2381206-8B9A-44A1-AD2F-B2661164AD94Q38935082-AE597626-7CCC-4CA3-9462-EA474C3A03FEQ42852118-F14CED0D-B8C7-479D-96A1-E97867625157Q45786541-D8FCEDAA-C47C-44B1-940A-6793BBD26EBEQ48949629-834B175D-E3FC-4581-B1C6-E168EE4F654EQ51739914-3A7B7CA9-AD51-4C74-AEAF-C8F61BEBBC9AQ51758973-C8136179-A194-4AB1-A78C-D2C62724761BQ55463112-9ED02AFA-00A7-4175-B1DF-D9205F7E7F6C
P2860
Comparative study on the immunogenicity between an HLA-A24-restricted cytotoxic T-cell epitope derived from survivin and that from its splice variant survivin-2B in oral cancer patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Comparative study on the immun ...... in-2B in oral cancer patients.
@en
Comparative study on the immun ...... in-2B in oral cancer patients.
@nl
type
label
Comparative study on the immun ...... in-2B in oral cancer patients.
@en
Comparative study on the immun ...... in-2B in oral cancer patients.
@nl
prefLabel
Comparative study on the immun ...... in-2B in oral cancer patients.
@en
Comparative study on the immun ...... in-2B in oral cancer patients.
@nl
P2093
P2860
P4510
P921
P356
P1476
Comparative study on the immun ...... in-2B in oral cancer patients.
@en
P2093
Akihiro Miyazaki
Akira Yamaguchi
Hiroyoshi Hiratsuka
Jun-ichi Kobayashi
Noriyuki Sato
Satomi Idenoue
Toshihiko Torigoe
Yoshihiko Hirohashi
P2860
P2888
P356
10.1186/1479-5876-7-1
P577
2009-01-06T00:00:00Z
P5875
P6179
1035496915